Hospitals have adopted a take-no-prisoners approach in the fight with Big Pharma over the 340B drug discount program. Can this strategy hold as Congress, oversight agencies, the courts and the Trump administration ratchet up scrutiny of the program?
HHS received over 3,000 comments on the Trump administration's Blueprint to Lower Drug Prices, which was released in May. Hospitals, health insurers and drugmakers had plenty to say on how to address soaring drug prices
Nivestym is not the first biosimilar of Neupogen, which helps chemotherapy patients recover, but it reflects the Food and Drug Administration's emphasis on bringing more biosimilars to market.
HHS is taking steps to remove legal protections for drug rebates that favor pharmacy benefit managers. It's unclear whether the changes will actually lead to lower drug prices, experts say.
The FDA is evaluating ways to make sure patients don't take an inappropriate over-the-counter drug. That could include adding information to the packaging label and offering online questionnaires to help people decide if a drug is right for them.
The Food and Drug Administration is forming a task force to find ways to improve the supply of crucial drugs. It's a new approach for the drug regulator, which has no control over companies.
Pfizer said it has agreed to "defer the company's price increases" to give President Donald Trump time to work on his drug pricing blueprint.
HHS is planning a new rule to set ceiling prices for the 340B drug discount program, despite many delays to implement an earlier rule on the issue.
On June 26, voters made Oklahoma the 31st state to legalize some form of medical marijuana. Nine of those states (and the District of Columbia) also have approved recreational use, so the legalized pot trade has become big business. In the eyes of the feds, all of this activity is still against the...
Rockwell Medical has responded to a whistle-blower lawsuit by its former CEO Rob Chioini and former CFO Thomas Klema by denying all allegations and countersuing the two former executives in federal court in Detroit.
The Teamsters union is urging its fellow McKesson Corp. shareholders to vote against the re-election of the drug distributor's audit committee chair at its annual shareholder meeting on July 25.
Walgreens Boots Alliance on Thursday reported that third-quarter earnings jumped more than 15%. But its stock price fell more than 9% after Amazon announced it's buying PillPack, an online pharmacy that delivers prescriptions.